Table 3. T cell–depleted conditioning... | American Society of Hematology

Table 3.

T cell–depleted conditioning (in vitro or in vivo).

Author, ref	N	Conditioning	T-depletion method	Age, y (range)	HLA SIB/other donor	chemo-sensitive, %	Median follow-up, mo	PFS, %	OS, %	TRM, %	Relapse, %	cGVHD, %
PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; Flu, fludarabine; Cy, cyclophosphamide; TBI, total-body irradiation; Mel, melphalan; BEAM, carmustine, etoposide, cytarabine, melphalan; E, extensive.
Mandigers³²	15	Cy/TBI	–	47 (30–57)	15/0	67	36mo	67	–	33	13	86
												43 E
Verdonck³³	10	Cy/TBI	Counter flow elutriation	43 (31–55)	10/0	30	25 mo	70	70	27	0	35
Juckett³¹	16	CyTBI	T10B9 in vitro	43 (27–62)	65%	31	64 mo	62	62	25	12	35
Morris³⁶	41	FluMel	Alemtuzumab in vivo	49 (18–73)	64%	98	16	49	74	8	44	0
Ingram³⁵	44	BEAM	Alemtuzumab in vivo	48 (31–59)	28/16	90	32	58	69	20	20	20
Novitzky³⁴	12	Myeloablative	Alemtuzumab in vitro	47 (21–57)	12/0	NS	26	–	75	16	8	18

Author, ref	N	Conditioning	T-depletion method	Age, y (range)	HLA SIB/other donor	chemo-sensitive, %	Median follow-up, mo	PFS, %	OS, %	TRM, %	Relapse, %	cGVHD, %
PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; Flu, fludarabine; Cy, cyclophosphamide; TBI, total-body irradiation; Mel, melphalan; BEAM, carmustine, etoposide, cytarabine, melphalan; E, extensive.
Mandigers³²	15	Cy/TBI	–	47 (30–57)	15/0	67	36mo	67	–	33	13	86
												43 E
Verdonck³³	10	Cy/TBI	Counter flow elutriation	43 (31–55)	10/0	30	25 mo	70	70	27	0	35
Juckett³¹	16	CyTBI	T10B9 in vitro	43 (27–62)	65%	31	64 mo	62	62	25	12	35
Morris³⁶	41	FluMel	Alemtuzumab in vivo	49 (18–73)	64%	98	16	49	74	8	44	0
Ingram³⁵	44	BEAM	Alemtuzumab in vivo	48 (31–59)	28/16	90	32	58	69	20	20	20
Novitzky³⁴	12	Myeloablative	Alemtuzumab in vitro	47 (21–57)	12/0	NS	26	–	75	16	8	18